FILE - In a Nov. 14, 2011 file photo customers enter and exit a Lowe's store in Saugus, Mass. Home improvement retailer Lowe’s Cos. said Monday, Feb. 25, 2013, cleanup efforts after Superstorm Sandy and its new pricing strategy helped its fourth-quarter net income surpass expectations. (AP Photo/Michael Dwyer, file)
-
FILE - In a Nov. 14, 2011 file photo customers enter and exit a Lowe's store in Saugus, Mass. Home improvement retailer Lowe’s Cos. said Monday, Feb. 25, 2013, cleanup efforts after Superstorm Sandy and its new pricing strategy helped its fourth-quarter net income surpass expectations. (AP Photo/Michael Dwyer, file)
-
This booking photo provided by the Clark County Detention Center in Las Vegas, Saturday, Dec. 22, 2012, shows 50-year-old Brenda Stokes, who also uses the name Brenda Wilson and Brenda Stokes Wilson. Police in Las Vegas have issued a plea for information about 10-year-old Jade Morris after she failed to return home Friday, Dec. 21, 2012, from a shopping trip with a woman who is thought to be Stokes. Stokes was arrested that night and accused of slashing the face of a female co-worker at the Bellagio resort on the Las Vegas Strip. She made her first appearance in Las Vegas Justice Court, Wednesday, Dec. 26, 2012. (AP Photo/Clark County Detention Center )
-
-
In this Thursday, Dec. 13, 2012 photo, amazon shipments are packaged in Koblenz, Germany. Amazon’s fourth-quarter net income fell 45 percent, as sharply higher revenue failed to keep pace with increased spending on order fulfillment and digital content, a trend that’s become the norm for the world’s largest online retailer. (AP Photo/dapd, Harald Tittel)
-
This undated photo provided by the Las Vegas Police Department shows Jade Moris, 10, who police are searching for after she failed to return home Friday, Dec. 21, 2012, from a shopping trip with a woman arrested that night and accused of slashing the face of a female co-worker at the Bellagio resort on the Las Vegas Strip. The woman, Brenda Stokes, 50, made her first appearance in Las Vegas Justice Court on Wednesday, Dec. 26, 2012. (AP Photo/Las Vegas Police Department)
-
This booking photo provided by the Clark County Detention Center in Las Vegas, Nev,. Saturday, Dec. 22, 2012, shows 50-year-old Brenda Stokes. Police in Las Vegas have issued a plea for information about 10-year-old Jade Morris after she failed to return home Friday, Dec. 21, 2012, from a shopping trip with a woman who is thought to be Stokes. Stokes was arrested that night and accused of slashing the face of a female co-worker at the Bellagio resort on the Las Vegas Strip. She made her first appearance in Las Vegas Justice Court Wednesday, Dec. 26, 2012. (AP Photo/Clark County Detention Center )
-
FILE - In this April 12, 2012 file photo, Las Vegas Sands Chairman and CEO Sheldon Adelson speaks at a news conference for the Sands Cotai Central in Macau. Casino giant Las Vegas Sands Corp. picked Madrid over Barcelona for a multi-billion dollar Spainish gambling resort project dubbed "EuroVegas." The Spanish capital, the country's largest city, emerged as the company's best choice for the development, Las Vegas Sands Chairman and CEO Sheldon Adelson said in a statement released late Friday, Sept. 7, 2012 in Las Vegas. (AP Photo/Kin Cheung, File)
Spectrum licenses Ligand multiple myeloma drug
NEW YORK (
AP) —
Spectrum Pharmaceuticals Inc. said Thursday it licensed a potential treatment for multiple myeloma from
Ligand Pharmaceuticals Inc.
Ligand's drug candidate is a form of melphalan, which is already used to treat multiple myeloma. The new form of the drug is designed to be given before the patient receives a round of autologous stem cell treatment, and the companies say it could allow for longer, safer, and stronger treatment because it could have fewer side effects.
The experimental formulation of melphalan eliminates ingredients that are reported to cause kidney and heart side effects. Those side effects force physicians to use smaller doses of the drug.
Multiple myeloma is a cancer of the blood that mainly affects older adults. Spectrum, based in Henderson, Nev., said about 20,000 cases are diagnosed each year.
The Food and Drug Administration has designated the treatment an orphan drug, which means similar products will be barred from the market for up to 7 years if it is approved. Spectrum is now responsible for clinical testing of the drug and expects to file for marketing approval in the first half of 2014.
Ligand said it will get an upfront license payment of $3 million and could receive more than $50 million in milestone payments. The San Diego company will also get royalties on sales of the drug if it is approved.
Ligand raised its financial guidance, saying it now expects to report net income of 47 to 51 cents per share in 2013 on $43 million to $46 million in revenue. It had forecast income of 35 to 39 cents per share on $41 million to $44 million in revenue.
Analysts expect net income of 41 cents per share and $43.1 million in revenue, according to FactSet.
For the first quarter, the San Diego company said its net income will be between 10 and 13 cents per share in the first quarter, and revenue will be between $10 million and $11 million. Analysts are forecasting a profit of 2 cents per share with $8.5 million in revenue on average.
Shares of Ligand rose 55 cents, or 2.5 percent, to $22.41 in afternoon trading, and Spectrum shares picked up 7 cents to $7.86.
Tags:
factset, cents, health, income, quarter, thursday, drug administration, royalties, blood, cases, percent, afternoon trading, companies, nev., treatment, effects, cancer, analysts, patient, net income, revenue, share, new york, license, drug, pharmacology, marketing approval, fewer side effects, licenses, physicians, spectrum, multiple myeloma, bone marrow, older adults, san diego company, similar products, clinical testing, financial guidance, potential treatment, orphan drug, drug candidate, new form, milestone payments, smaller doses, stronger treatment, spectrum pharmaceuticals inc., spectrum shares, ligand, ligand multiple myeloma, autologous stem cell, ligand pharmaceuticals, melphalan eliminates ingredients, upfront license payment, experimental formulation, heart side effects, melphalan
Print Page
